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a b s t r a c t
Background: Single positive staphylococcal blood culture in a hematopoietic stem cell
transplantation (HSCT) recipient is generally regarded as contamination. Such a blood
culture (BC) does not fill the criteria for Laboratory-Confirmed Bloodstream Infection
(LCBI) and could be described as Single Positive Commensal Blood Culture. The aim of
this retrospective cohort analysis was to determine the clinical significance of SPCBC in
HSCT recipients. Methods: 206 patients transplanted between 2007 and 2013 were follo-
wed until January 2015. Results: The 100-day survival for patients without positive BC
was 99.6% compared with 83.9% for LCBI and 82.8% for SPCBC ( p = 0.0036). The 5-year
overall survival (5yOS) was 67.1% for patients without positive BC, 44.9% for LCBI, 34.0%
for SPCBC ( p < 0.0001). The per-day risk of developing SPCBC was identical in autologous
and allogenic transplantation. SPCBC remained a significant factor for reduced 5yOS after
HSCT in the univariate analysis (HR 2.52, 1.26–5.02, p = 0.0001) as well as in the multiva-
riate analysis (HR 2.21, 1.26–3.87, p = 0.006). SPCBC consisted solely of different Staphylo-
coccus species with dominance of Staphylococcus epidermidis (64% of SPCBC). Conclusion:
To our knowledge this is the first report that specifically shows that short- and long-term
survival after HSCT is significantly lower in patients who experience an episode of SPCBC
with Staphylococcus spp. during HSCT hospitalization.
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Bloodstream infections (BSI) are a major risk of severe
complications for patients after hematopoietic stem cell
transplantation (HSCT) [1–4]. Staphylococcus spp. bacteria are
part of the normal skin flora and are regarded as one of the
leading causes of nosocomial infections [5, 6]. Even though
Staphylococci are found in a significant proportion of blood
cultures collected from patients after HSCT, their presence
is often underestimated. Moreover, there are no separate
analyses of survival of patients with staphylococcal BSI after
HSCT in current studies [1–3]. The role of staphylococcal BSI
is more acknowledged in neonatal late onset sepsis, which
is most often associated with indwelling medical devices [7].
In infants with very low birth weight, mortality rates for
Staphylococcus epidermidis BSI, for example, range from 1.5%
to 10.2%, showing that bloodstream infection by this patho-
gen cannot be simply regarded as a “contamination”.
European Centre for Disease Prevention and Control
(ECDC) and Centres for Disease Control and Prevention
(CDC) diagnostic criteria of Bloodstream Infection (BSI),
Laboratory-Confirmed Bloodstream Infection (LCBI) or Cen-
tral Line Associated Bloodstream Infection (CLABSI) require
at least two positive blood cultures with common skin
contaminant, e.g. Staphylococcus spp., for the diagnosis to be
established [8, 9]. A single positive culture with Staphylococ-
cus epidermidis in HSCT patient (with or without symptoms
of infection) under current guidelines is not classified as BSI
or LCBI. For the purpose of this analysis we classified those
cases as Single Positive Commensal Blood Cultures (SPCBC)
– a definition that would include all cases of patients with
single commensal cultures, with or without other clinical
symptoms of infection.
Due to the clinical characteristics of some patients with
SPCBC during the HSCT hospitalization, we hypothesized
that SPCBC within this group of patients might influence
the outcome of transplantation.
In this publication, we show that the HSCT patients who
have an episode of SPCBC (i.e. a single positive blood culture
of Staphylococcus spp.) during the transplant hospitalization,
have significantly higher short- and long-term mortality.
While all of those cases did not fulfil the criteria for BSI,
LCBI or CLABSI, we were able to show their significant
influence on outcome after HSCT.
Patients and methods
This study was a retrospective cohort analysis of consecu-
tive adult patients who underwent autologous or allogeneic
haematological stem cell transplantations at the Depart-
ment of Haematology, Oncology and Internal Medicine of
the Medical University of Warsaw.
In 2006 we set up an electronic medical record system
for storing the hematopoietic stem cell transplantation
recipients’ information. It recorded data necessary for EBMT
and CIMBTR reports and excerpts from patients’ discharge
summaries – including significant microbiological data –
that could be systematically evaluated. This allowed us togather clinical information about patients after standard
hematopoietic stem cell transplantation which exceeded the
basic standards required for EBMT and CIMBTR data report-
ing.
Patients’ data were collected and entered into the data-
base between December 2006 and March 2013. After con-
cluding an internal audit that excluded incomplete or
incompatible records, we began the final analysis. Patients’
outcomes were followed until their death or the cut-off date
of December 31, 2014. Response to therapy, relapse, and
survival data were updated continuously. No patients were
lost to follow-up. All the information concerning demo-
graphics, type of underlying disease, transplant type, and
survival was noted. All patients gave written, informed
consent allowing the use of their medical records for
research. The study was approved by Local Institutional
Ethics Board.
Prophylaxis and management of infections
Patients received standard antimicrobial prophylaxis with
ciprofloxacin, antiviral prophylaxis with acyclovir, and anti-
fungal prophylaxis with fluconazole during the HSCT hospi-
talization. Central venous catheters were placed on the first
day after admission to the hospital and were removed on
the day of discharge. Non-tunnelled double lumen central
venous catheters were placed in subclavian vein as
a standard in HSCT patients. In cases where CVC had to be
removed because of infections, the next CVC has been
inserted on the same or next day.
In case of fever (pyrexia of 38 8C) or other signs or
symptoms of infection, prophylactic antibiotics were
stopped and blood cultures were taken. Patients were
treated with broad-spectrum intravenous antibiotics at the
discretion of the attending physicians until the results of
the bacterial cultures were known. The first line antibiotic
therapy standard of the centre was piperacillin/tazobactam
with amikacin. Other antibiotics were introduced according
to the results of the bacterial cultures. If the patient
developed signs of septic shock or the symptoms persisted
more than 48 h, meropenem or imipenem/cylastatin were
added. Fungal infection diagnostic and treatment has been
initiated in cases of persistent fever (>96 h), suspected or
confirmed fungal infection. In cases of CMV reactivation
patients were treated with ganciclovir or other antivirals.
Antibiotics were modified according to the susceptibility of
all organisms isolated.
Bloodstream infection
All blood cultures (BC) were obtained in response to clinical
suspicion of infection, usually fever (pyrexia of 38 8C), malaise,
or rash near the site of central venous catheter insertion, or
after physician's request (usually when other clinical signs
made infection probable). As a standard two sets (aerobic and
anaerobic) of blood cultures were taken – one from periphery
and one from central line. If there was no bacterial growth
and fever persisted subsequent sets of BC were taken.
Blood specimens were tested using BD BACTEC bottle
culture qualitative test. Kirby-Bauer disc diffusion test was
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cultures. Etest was used when the data on antibiotic
susceptibility could not be obtained otherwise. EUCAST
guidelines were followed in all steps of microbiological
testing [10].
Bloodstream infection (BSI) was defined as presence of
any positive bacterial blood culture in a patient. Laboratory-
Confirmed Bloodstream Infection (LCBI) was defined in
accordance with the guidelines for Bloodstream Infection
Event specified by Centres for Disease Control and Preven-
tion as a recognized pathogen identified from one or more
blood specimens that was not related to an infection at
another site [9]. Single Positive Commensal Blood Culture
(SPCBC) was diagnosed in cases of identification of
a common commensal (in line with CDC organism list) [11]
from one blood culture that was not related to an infection
at another site regardless of other symptoms (e.g. fever
[>38.0 8C], chills, or hypotension).
The patient was defined as having no bloodstream
infection if no bacteria were identified in any blood cultures.
An infection was considered polymicrobial if two or more
pathogens were isolated from a blood culture.
Definitions
The criterion for engraftment was the first of three days
with an absolute neutrophil count of 500/mm3 or greater as
per EBMT guidelines [12]. Acute GvHD was graded according
to standard criteria [13]. The maximum grade of acute GvHD
that developed in each patient was used.
Statistics
All statistical calculations were done using MedCalc Statis-
tical Software version 15.10 (MedCalc Software bvba, Ostend,
Belgium). In all analyses, a p-value of <0.05 was considered
statistically significant.
For the comparison between groups of medians of
continuous variables, the Mann–Whitney U test was used.
For the comparison between groups of categorical variables,
the Chi-squared test was used. Univariate survival analysis
was performed using Kaplan–Meier survival analysis regres-
sion reporting hazard ratios (HR) and 95% confidence inter-
vals (CI). Multivariate survival analysis was performed using
Cox proportional hazards regression reporting hazard ratios
(HR) and 95% confidence intervals (CI). For multivariate
analyses, all variables from univariate analysis that had a p-
value less than or equal to 0.05 were included.
When testing acute GvHD, degree of HLA matching or
acute myeloid leukaemia as a predictor of mortality, we
adjusted for the type of HSCT. This was done in order to
minimize the probability of confounding, since, in this
cohort, acute myeloid leukaemia was treated only with
allogeneic transplantations, and GvHD and HLA matching
do not pose a problem when autologous transplantation is
performed.
Variables analyzed included age, sex, type of HSCT, HLA
matching, acute GvHD, neutropenic fever, cytomegalovirus(CMV) infection reactivation and time to engraftment. Type
of blood culture (SPCBC or LCBI) was additionally examined
in the mortality analysis.
Results
206 patients with haematological malignancies receiving
autologous and allogenic HSCT between 2006 and 2013 were
identified for the study. All patients had complete and
validated medical records; all of them completed the follow-
up and their data were gathered and analyzed. Median time
of follow-up was 36 months (range 0.77–80.0).
General characteristics of patients included in the study
are listed in Table I. Median time from transplantation to
discharge (or death) for all HSCT recipients was 22 days.
Hundred-day survival rate was 92.7%, three-year survival
rate was 65.7%, while five-year survival rate was 59.1%.
Microbiology
60 (29.1%) patients had at least one positive bacterial blood
culture (Tab. I). Thirty-one (15%) patients had a Laboratory-
Confirmed Bloodstream Infection while 29 (14.1%) patients
had a Single Positive Commensal Blood Culture. There were
no patients with both LCBI and SPCBC pathogens. Antibio-
tic-resistant species were isolated from 16 (7.7%) patients,
8 in the LCBI and 8 in the SPCBC group.
Seventy-one positive microbiologic blood isolates were
obtained in total; 9 patients had a positive blood culture
with two or more pathogens simultaneously. There were no
patients who had a positive blood culture on more than one
occasion. Gram-positive bacteria were found in 40 (56.3%)
blood cultures and Gram-negative bacteria were found in 31
(43.7%) blood cultures. Pathogens from each group are listed
in Table II. The most common pathogen in SPCBC group
was Staphylococcus epidermidis, which constituted 63.3% of
SPCBC isolates and 29.6% of all isolates. Staphylococcus spp.
species constituted all of SPCBC isolates. There were no
fungal isolates.
The frequency of all positive BC was significantly higher
in allogeneic HSCT when compared to autologous transplan-
tations (34.9% vs. 13.4%, p = 0.001). LCBI were more frequent
in the allogeneic transplantation recipients (19.2% vs. 4.3%,
p = 0.0062), while SPCBC frequency did not differ signifi-
cantly between allogeneic and autologous transplants (15.8%
vs. 8.7%, p = 0.2099).
The frequency of antibiotic-resistant species was similar
in LCBI and SPCBC patients (25.8% vs. 27.6%, p = 0.8916).
The risk of having a positive BC was 1.21% per day of
hospitalization; the risk of LCBI was 0.60% per day of
hospitalization and the risk of SPCBC was 0.61% per day of
hospitalization. There was no statistically significant differ-
ence in the risk of having a positive BC per day of
hospitalization between allogeneic and autologous HSCT
recipients (1.35% vs. 0.91%, p = 0.158). Likewise, there was no
statistically significant difference in LCBI (0.72% vs. 0.35%,
p = 0.760) and SPCBC (0.63% vs. 0.56%, p = 0.760) per hospita-
lization day risk between allogeneic and autologous trans-
plant patients.
Table I – General data of the patients included in the study
Characteristics All patients (%) No BC (%) SPCBC (%) LCBI (%)
Number of patients 206 (100) 146 (70.9) 29 (14.1) 31 (15.0)
Median age on admission (min–max) [years] 37 (18–66) 36 (18–66) 44 (18–59) 44 (20–65)
Median BMI (IQR) 25.0 (22.3, 28) 24.3 (21.6, 27.7) 25.5 (22.6, 28.9) 25.7 (23.6, 28.3)
Gender
Female 94 (45.6) 68 (46.6) 11 (37.9) 15 (48.4)
Male 112 (54.4) 78 (53.4) 18 (62.1) 16 (51.6)
Type of transplantation
Autologous 67 (32.5) 58 (39.7) 6 (20.7) 3 (9.7)
Allogeneic 139 (67.5) 88 (60.3) 23 (79.3) 28 (90.3)
Underlying disease
Acute myeloid leukaemia 67 (32.5) 39 (26.7) 14 (48.3) 14 (45.2)
Other than acute myeloid leukaemia 139 (67.5) 107 (73.3) 15 (51.7) 17 (54.8)
CMV reactivation
Absent 193 (93.7) 137 (93.8) 27 (93.1) 29 (93.5)
Present 13 (6.3) 9 (6.2) 2 (6.9) 2 (6.5)
HLA match
10 of 10 190 (92.2) 139 (95.2) 25 (86.2) 26 (83.9)
9 of 10 16 (7.8) 7 (4.8) 4 (13.8) 5 (16.1)
Acute GvHDa
GvHD 0-II 195 (94.7) 141 (96.6) 26 (89.7) 28 (90.3)
GvHD III-IV 11 (5.3) 5 (3.4) 3 (10.3) 3 (9.7)
Neutropenic fever
Present 86 (41.7) 74 (50.7) 5 (17.2) 7 (22.6)
Absent 120 (58.3) 72 (49.3) 24 (82.8) 24 (77.4)
Time to engraftment (IQR) [days] 15 (12, 19) 14 (11, 18) 18 (13, 22) 16 (14, 20)
Time from transplantation to discharge (IQR) [days] 22 (16, 29) 21 (15, 28) 26 (20, 30) 26 (21, 39)
Overall survival
Survived 126 (61.2) 101 (69.2) 11 (37.9) 14 (45.2)
Died 80 (38.8) 45 (30.8) 18 (62.1) 17 (54.8)
IQR – interquartile range; BC – blood culture; SPCBC – Single Positive Commensal Blood Culture; LCBI – Laboratory-Confirmed Bloodstream
Infection; BMI – body mass index; GvHD – graft versus host disease
a Adjusted for the type of HSCT.
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The median time from transplantation to discharge (and
interquartile range) in subjects without positive BC was 21
days (15, 28 days), in subjects who developed LCBI it was 26Table II – Bacterial cultures within SPCBC and LCBI groups

















LCBI – Laboratory-Confirmed Bloodstream Infection; SPCBC –
Single Positive Commensal Blood Culture.days (21, 39 days, p = 0.0005), and in subjects who developed
SPCBC it was 26 days (20, 30 days; p = 0.0155).
Hundred-day survival rate was 99.6% in the patients
without positive BC, 83.9% in the LCBI group and 82.8% in
the SPCBC group ( p = 0.0036). Three-year survival rate was
75.0% in the group without positive BC, 44.9% in the LCBI
group and 40.8 in the SPCBC group ( p = 0.0004). Five-year
survival rate was 67.1% in the subjects without positive BC,
44.9% in the LCBI group and 34.0% in the SPCBC group
( p < 0.0001) (Fig. 1, Tab. III). Additionally, survival between
LCBI and SPCBC groups did not differ significantly at any of
those times (Tab. IV).
In a univariate analysis, age over 40 years, allogeneic
HSCT, time to engraftment, acute GVHD grades III–IV, LCBI,
and SPCBC, were risk factors for mortality. Conversely,
gender, degree of HLA mismatch between donor and recipi-
ent, acute myeloid leukaemia, CMV reactivation or neutro-
penic fever were not found to significantly influence
survival (Tab. V).
In the multivariable analysis of mortality, the variables
such as age on admission over 40 years, type of HSCT, acute
GVHD grades III and IV, time to engraftment over 15 days,
and type of blood culture were integrated. After adjusting
for other variables, both LCBI and SPCBC were still indepen-
dent predictors of mortality (Fig. 2). Mortality was also
independently influenced by age on admission over 40 years
and presence of acute GvHD grades III and IV (Tab. VI).
Fig. 1 – Mortality associated with positive blood cultures after HSCT
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The current definitions of LCBI and CLABSI downplay the
meaning of single positive blood culture with bacteria
regarded as common human commensals even in the
presence of clinical symptoms of the disease [8, 9]. Our
results show that in HSCT patients with a positive blood
culture, even a single staphylococcal isolate (including
Staphylococcus epidermidis) is associated with higher long-
term mortality.
The common perception of this bacteria species relies on
definition of LCBI – they are treated as contaminants unless
two separate cultures are positive. This playing down of
staphylococci is also present in analyses of infectiousTable III – 100-day, 3-year and 5-year survival rates in
patients with LCBI and SPCBC, and no BC
No BC LCBI SPCBC p-value
100-day survival rate 99.6% 83.9% 82.8% 0.0036
3-year survival rate 75.0% 44.9% 40.8% 0.0004
5-year survival rate 67.1% 44.9% 34.0% <0.0001
LCBI – Laboratory-Confirmed Bloodstream Infection; SPCBC –
Single Positive Commensal Blood Culture; No BC – patients without
positive blood cultures.
Table IV – 100-day, 3-year and 5-year survival rates in
patients after LCBI and SPCBC
LCBI SPCBC p-value
100-day survival rate 83.9% 82.8% 0.8830
3-year survival rate 44.9% 40.8% 0.9026
5-year survival rate 44.9% 34.0% 0.7935
LCBI – Laboratory-Confirmed Bloodstream Infection; SPCBC –
Single Positive Commensal Blood Culture.complications after HSCT – they do not include separate
survival graphs for patients with coagulase negative staphy-
lococci (CNS) although those bacteria constitute often more
than 50% of infections in HSCT patients at some centres.
Is a positive staphylococcal blood culture a causative
factor of increase in mortality or does increased suscept-
ibility to this commensal reflect changes in patient subpo-
pulation caused by general poorer clinical condition? We
show that the risk of SPCBC per day of hospitalization is
almost identical in allogeneic and autologous transplanta-
tions, and it remains an independent risk factor for lower
survival in multivariate analysis. As there is new data that
shows that the early use of antibiotics might lower the
long-term survival of the patients after HSCT the findings of
this work might also reflect the increased use of antibiotics
in this group of patients [14]. The early SPCBC could be
a trigger to the use of antibiotics with further changes to
the bacterial flora of the recipient that could later lead to
lower survival. As the short-term mortality and long-term
survival after LCBI and SPCBC are similar, we have to look
at the similarities between those cases that could explain
those findings. The results of our work indicate that the
SPCBC is not an indicator of status of the patients and very
likely plays a prominent role in a cascade of factors leading
to increased mortality among HSCT recipients.
One of the key factors in prevention of staphylococcal
SPCBC is quality of CVC maintenance in HSCT patients –
would it be possible to substantially improve survival after
HSCT just by improving the prevention of CLABSI? We know
that the CVC standards might still not be optimal in many
HSCT centres and that the improvement of these standards
is needed [15]. It would be very interesting to see if the
improvement of CLABSI prevention leads to better long-term
survival after HSCT.
There are several limitations to this study. Autologous
and allogenic transplantations are analyzed together. Survi-
val in both groups does differ significantly reflecting differ-
ences between those types of transplantations. However,
Table V – Potential univariate predictors of mortality
Potential predictor Died (%) Survived (%) HR (95% CI) p-value
Age on admission greater than 40 years
Under 40 years 31 (28.4) 78 (71.6) 1.00 0.0010
Over 40 years 49 (50.5) 48 (49.5) 2.08 (1.34–3.24)
Gender
Male 41 (36.6) 71 (63.4) 1.00 0.4367
Female 39 (41.9) 54 (58.1) 1.19 (0.77–1.85)
Type of transplantation
Autologous 15 (22.4) 52 (77.6) 1.00 0.0004
Allogeneic 65 (46.8) 74 (53.2) 2.63 (1.68–4.14)
Underlying diseasea
Other than acute myeloid leukaemia 42 (30.2) 97 (69.8) 1.00 0.0639
Acute myeloid leukaemia 38 (56.7) 29 (43.3) 1.59 (0.98–2.61)
HLA matcha
10 of 10 59 (46.5) 68 (53.5) 1.00 0.4272
9 of 10 9 (56.3) 7 (43.8) 1.32 (0.61–2.9)
CMV reactivationa
Absent 58 (46) 68 (54) 1.00 0.8721
Present 6 (46.2) 7 (53.8) 0.93 (0.39–2.22)
Acute GvHDa
GvHD 0-II 56 (43.8) 72 (56.2) 1.00 0.0211
GvHD III-IV 8 (72.7) 3 (27.3) 2.33 (0.82–6.66)
Neutropenic fever
Absent 45 (37.5) 75 (62.5) 1.00 0.8567
Present 35 (40.7) 51 (59.3) 1.04 (0.67–1.62)
Time to engraftment
Under 15 days 32 (30.2) 74 (69.8) 1.00 0.0027
Over 15 days 47 (49.0) 49 (51.0) 1.96 (1.26–3.07)
Presence of a positive blood culture
No 44 (30.1) 102 (69.2) 1.00 0.0001
Yes 35 (58.3) 25 (41.7) 2.64 (1.56–4.50)
Type of blood culture
No BC 45 (30.8) 101 (69.2) 1.00
LCBI 17 (54.8) 14 (45.2) 2.52 (1.26–5.02) 0.0065
SPCBC 18 (62.1) 11 (37.9) 2.68 (1.34–5.36) 0.0016
a Adjusted for HSCT type.
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groups and almost identical when per diem rates are
included. This suggests that the time of hospitalization
might be the most important factor in patient populationFig. 2 – Independent factors of mortality (multivariate analysis). L
Single Positive Commensal Blood Culturewith central venous catheter inserted for the whole period
of hospitalization. We feel that the data from autologous
HSCT is an important addition to this study, putting
into perspective data from allogenic HSCT. Moreover, theCBI – Laboratory-Confirmed Bloodstream Infection; SPCBC –





Age on admission over 40 years 2.04 (1.26–3.29) 0.0038
Allogeneic HSCT 1.41 (0.69–2.90) 0.3521
Acute GvHD, grades III and IV 3.01 (1.40–6.46) 0.0048
Time to engraftment over 15 days 1.27 (0.73–2.21) 0.3996
LCBI 2.05 (1.15–3.67) 0.0162
SPCBC 2.21 (1.26–3.87) 0.006
LCBI – Laboratory-Confirmed Bloodstream Infection; SPCBC –
Single Positive Commensal Blood Culture.
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allogenic or autologous HSCT has on long-term mortality
from the effect SPCBC – and this part of analysis shows
early SPCBC as an independent risk factor for mortality after
HSCT. We were only able to analyze the aGvHD occurrence
in the timeframe shortly after the transplantation and the
study database was not designed to analyze causes of long-
term non-transplantation related mortality in the groups
(such as infection, GvHD, or recurrent and refractory dis-
ease). The knowledge of these factors could greatly improve
our understanding of factors contributing to higher mortal-
ity after the SPCBC. It could be argued that SPCBC appears
only in patients who are in worse general condition prior to
transplantation and have reduced survival which is rather
caused by underlying disease than SPCBC. However, even if
this statement was true it would not explain why short-
term and long-term mortality after SPCBC and LCBI is
similar – where latter is caused by more virulent bacteria
species. Staphylococcus epidermidis sepsis frequency seems to
depend on common factors present in allo and auto HSCT
setting, such as CVC presence, time of hospitalization and
time of neutropenia.
Contradicting the general view of Staphylococcus spp. as
relatively unimportant commensals and contaminants, we
show that the short- and long-term mortality in patients
who have at least one positive culture with this bacterium
is similar to mortality among patients after sepsis with
more virulent strains of bacteria. This raises a question if
current LCBI definitions are appropriate for this patient
population and how the early SPCBC contributes to short
and long-term mortality after HSCT.
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